Physician profile
Timothy C Bothwell
NPI 1780680850
$1,047.29
in general payments reported to CMS, 2019-2025
24 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2021: $11.53 · 2022: $66.28 · 2023: $205 · 2024: $420 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $252.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $137.35 | 2019-2025 | |
| Novo Nordisk INC | $124.02 | 2019-2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $70.07 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $68.15 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $67.46 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $34.92 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $25.79 | 2019 | |
| Inspire Medical Systems, INC. | $22.87 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $21.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.93 | 2023 | |
| Phadia US INC. | $19.11 | 2023 | Immunocap |
| Abbott Laboratories | $18.14 | 2023 | Freestyle Libre 3 |
| Abbvie INC. | $17.72 | 2023 | Linzess, Viberzi |
| Astellas Pharma US INC | $17.31 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $17.08 | 2024 | Senza |
| Phathom Pharmaceuticals, INC. | $15.87 | 2024 | Voquezna |
| Insulet Corporation | $15.26 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $15.17 | 2024 | Keveyis |
| Amgen INC. | $14.75 | 2024 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $14.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.64 | 2024 | |
| Amarin Pharma, INC. | $12.47 | 2019 | |
| Hologic Sales and Service, LLC | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Bothwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.